Plus: FDA greenlights new antibiotic for cUTIs, and ASCO meeting addresses grief in oncology care.
Type 2 diabetes diagnoses in women under 40 rose by 47 percent between 2017/18 and 2023/24, double the rate for women aged 40 to 79 and highlighting unmet needs in preventative care. Concurrently, the Society for Maternal-Fetal Medicine confirmed acetaminophen as the safest first-line treatment for pain and fever during pregnancy, impacting maternal health providers. New research leveraging 94,000 nights of smartwatch data reveals increased awake time post-menopause, informing femtech platforms. Five takes inside, plus a quick-hits roundup.
VIA FemTech World
Diagnoses of type 2 diabetes in women under 40 rose by 47 percent between 2017/18 and 2023/24, double the rate for women aged 40 to 79. Only 57 percent of women with GDM received an annual HbA1c test, and 4.5 percent received support through the NHS Diabetes Prevention Programme. More than a third of women with GDM reported feeling abandoned by healthcare services after giving birth, impacting a population where 11 percent develop prediabetes and 15 percent develop type 2 diabetes post-GDM. These statistics highlight unmet needs in preventative care and postpartum support for women in the UK, creating opportunities for femtech solutions.
Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN
The Society for Maternal-Fetal Medicine confirmed acetaminophen as the safest first-line treatment for pain and fever during pregnancy. This updated consensus statement impacts maternal health providers and product manufacturers.
Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN
The FDA approved Wockhardt’s novel intravenous antibiotic, cefepime and zidebactam. It targets multiple penicillin-binding proteins to treat adults with complicated urinary tract infections. This approval provides clinicians with a new treatment option for a common condition affecting women.
Read the full story →
— The Luteal Editorial Team
VIA STAT News
This year's American Society of Clinical Oncology (ASCO) annual meeting, traditionally focused on survival data, shifted to include conversations about grief and loss. Outgoing ASCO President Eric Small spoke about his partner, Amy Lin, who died in December from metastatic clear cell ovarian cancer. Small also invited grief expert David Kessler to speak on compassionate end-of-life care, highlighting an evolving focus for oncology and gynecological cancer care providers.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
Researchers analyzed over 94,000 nights of sleep data from 338 participants in the Apple Women’s Health Study. The study found 60% of women experienced increased wake after sleep onset (WASO) and a 0.8% increase in awake time post-menopause. This data suggests opportunities for femtech platforms to leverage wearables for tracking and managing perimenopausal sleep changes.
Read the full story →
— The Luteal Editorial Team